TY - JOUR
T1 - Vasoactivity of arachidonic acid epoxides
AU - Carroll, Mairead A.
AU - Schwartzman, Michal
AU - Capdevila, Jorge
AU - Falck, J. R.
AU - McGiff, John C.
N1 - Funding Information:
The authors thank Dr. M.C. Carrara for her technical assistance. This work was supported by Program Project Grant No. PO-HL34300, American Heart Association Grant No 86 1122, NIH-GM37922, NIH GM31278. M.S. ~s a recaplent of Irma T Hirschl Career Scientist Award.
PY - 1987/6/19
Y1 - 1987/6/19
N2 - Arachidonic acid (AA) can be metabolized to epoxides and their corresponding diols via the cytochrome P450 epoxygenase pathway. We have compared the vascular activity of four sythetically prepared epoxyeicosatrienoic acids, i.e. 5.6-, 8,9-, 11,12- and 14,15-EET (2-20 μM) on the isolated perfused rat tail artery. The 5,6-EET was equipotent with acetylcholine in dose dependently reducing vascular resistance (ED50 = 3.4 ± 0.5 μM). The 8,9-, 11,12- and 14,15-EETs of AA did not affect vascular resistance; neither did the 5,6-DHET and δ-lactone, hydrolysis products of 5,6-epoxide. We suggest that the 5,6-epoxide, in contrast to other cytochrome P450-derived products, contributes to the regulation of regional vascular tone.
AB - Arachidonic acid (AA) can be metabolized to epoxides and their corresponding diols via the cytochrome P450 epoxygenase pathway. We have compared the vascular activity of four sythetically prepared epoxyeicosatrienoic acids, i.e. 5.6-, 8,9-, 11,12- and 14,15-EET (2-20 μM) on the isolated perfused rat tail artery. The 5,6-EET was equipotent with acetylcholine in dose dependently reducing vascular resistance (ED50 = 3.4 ± 0.5 μM). The 8,9-, 11,12- and 14,15-EETs of AA did not affect vascular resistance; neither did the 5,6-DHET and δ-lactone, hydrolysis products of 5,6-epoxide. We suggest that the 5,6-epoxide, in contrast to other cytochrome P450-derived products, contributes to the regulation of regional vascular tone.
KW - Arachidonic acid
KW - Cytochrome P450
KW - Epoxides
KW - Vasodilatation
UR - http://www.scopus.com/inward/record.url?scp=0023182989&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023182989&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(87)90445-6
DO - 10.1016/0014-2999(87)90445-6
M3 - Article
C2 - 3622613
AN - SCOPUS:0023182989
SN - 0014-2999
VL - 138
SP - 281
EP - 283
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 2
ER -